14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -2.339 3 days ( 0.80 % )
Last Price £0.185 0.98 %
High/ Low £0.180 - £0.200 5.56%
Chg 7 Days -2.63 % $0.190 £0.185
Chg 30 Days -2.63 % $0.190 £0.185
Chg 12 mos -24.49 % $0.245 £0.185
Trend - 3 mos -38.89 % Width: 75.28 %
Trend - 12 mos -1.13 % Width: 128.78 %
Pred. range - 3 mos £0.0831 - £0.146 -55.09 % - -21.28 %
Pred. range - 12 mos £0.178 - £0.406 -3.98 % - 119.67 %
Short MA avg 3 mos Buy Apr 18, 2024 - 5 days
Long MA avg 3 mos Buy Apr 18, 2024 - 5 days
Short/Long MA avg 3 mos Sell Jan 31, 2024 - 59 days
Short MA avg 12 mos Buy Apr 18, 2024 - 5 days
Long MA avg 12 mos Buy Feb 05, 2024 - 56 days
Short/Long MA avg 12 mos Sell Feb 21, 2024 - 44 days
Pivot Short Sell Mar 27, 2024 - 19 days
Bollinger Buy Nov 30, -1 - N/A days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Newfield Exploration Company

Newfield Exploration Company Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an optio... NFX.L Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT